Physician profile
Susan Hake
NPI 1558325373
$1,806.15
in general payments reported to CMS, 2019-2025
24 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $188 · 2021: $83.52 · 2023: $109 · 2024: $535 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $200.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.78 | 2019-2024 | Ofev, Jardiance |
| Astellas Pharma US INC | $146.94 | 2019-2024 | Veozah |
| Pfizer INC. | $145.46 | 2019-2024 | |
| Amgen INC. | $112.86 | 2019-2025 | Evenity |
| Lilly USA, LLC | $108.36 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $107.44 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $69.01 | 2019 | |
| Amarin Pharma, INC. | $52.37 | 2019 | |
| Allergan, INC. | $51.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.16 | 2019 | |
| Exact Sciences Corporation | $38.89 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $38.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.52 | 2023-2024 | Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.00 | 2019-2020 | |
| Axsome Therapeutics, INC. | $20.55 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $19.70 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.06 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $16.50 | 2020 | |
| Abbott Laboratories | $14.82 | 2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $12.91 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Hake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.